These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17325102)

  • 1. Coverage and prior authorization of psychotropic drugs under Medicare Part D.
    Huskamp HA; Stevenson DG; Donohue JM; Newhouse JP; Keating NL
    Psychiatr Serv; 2007 Mar; 58(3):308-10. PubMed ID: 17325102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating Medicare Part D's impact on medication access among dually eligible beneficiaries with mental disorders.
    Donohue JM; Frank RG
    Psychiatr Serv; 2007 Oct; 58(10):1285-91. PubMed ID: 17914004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual eligibles with mental disorders and Medicare part D: how are they faring?
    Donohue JM; Huskamp HA; Zuvekas SH
    Health Aff (Millwood); 2009; 28(3):746-59. PubMed ID: 19414883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of Part D for mentally ill dual eligibles: a challenge for Medicare.
    Morden NE; Garrison LP
    Health Aff (Millwood); 2006; 25(2):491-500. PubMed ID: 16522603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication access and continuity: the experiences of dual-eligible psychiatric patients during the first 4 months of the Medicare prescription drug benefit.
    West JC; Wilk JE; Muszynski IL; Rae DS; Rubio-Stipec M; Alter CL; Narrow WE; Regier DA
    Am J Psychiatry; 2007 May; 164(5):789-96. PubMed ID: 17475738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicare Part D and nursing home residents.
    Stevenson DG; Huskamp HA; Keating NL; Newhouse JP
    J Am Geriatr Soc; 2007 Jul; 55(7):1115-25. PubMed ID: 17608889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-year Medicare Part D prescription drug benefits: medication access and continuity among dual eligible psychiatric patients.
    West JC; Wilk JE; Rae DS; Muszynski IL; Rubio-Stipec M; Alter CL; Sanders KE; Crystal S; Regier DA
    J Clin Psychiatry; 2010 Apr; 71(4):400-10. PubMed ID: 19925748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicare part D and decompensation.
    Park JM; Hariprasad R; Park LT
    Psychiatr Serv; 2006 May; 57(5):722-3. PubMed ID: 16675773
    [No Abstract]   [Full Text] [Related]  

  • 9. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. State Medicaid prescription drug expenditures for Medicare-Medicaid dual eligibles: estimates of Medicaid savings and federal expenditures resulting from expanded Medicare prescription coverage.
    Dale SB; Verdier JM
    Issue Brief (Commonw Fund); 2003 Apr; (627):1-12. PubMed ID: 12685428
    [No Abstract]   [Full Text] [Related]  

  • 11. Managing psychotropic drug costs: will formularies work?
    Huskamp HA
    Health Aff (Millwood); 2003; 22(5):84-96. PubMed ID: 14515884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Access to cancer drugs in Medicare Part D: formulary placement and beneficiary cost sharing in 2006.
    Bowman J; Rousseau A; Silk D; Harrison C
    Health Aff (Millwood); 2006; 25(5):1240-8. PubMed ID: 16966719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying widely covered drugs and drug coverage variation among Medicare part D formularies.
    Tseng CW; Mangione CM; Brook RH; Keeler E; Dudley RA
    JAMA; 2007 Jun; 297(23):2596-602. PubMed ID: 17579228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Medicare Part D on mental health treatment and outcomes for dual eligible beneficiaries with HIV.
    Belenky N; Pence BW; Cole SR; Dusetzina SB; Edmonds A; Oberlander J; Plankey M; Adedimeji A; Wilson TE; Cohen J; Cohen MH; Milam JE; Adimora AA
    AIDS Care; 2019 Apr; 31(4):505-512. PubMed ID: 30189747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Medicare Part D coverage gap: implications for non-dually eligible older adults with a mental illness.
    Bakk L; Woodward AT; Dunkle RE
    J Gerontol Soc Work; 2014; 57(1):37-51. PubMed ID: 24377835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Per-patient-per-month drug costs in Medicare Part D protected classes.
    Mucha L; Masia NA; Axelsen KJ
    Pharmacoeconomics; 2006; 24 Suppl 3():79-84. PubMed ID: 17266390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the Medicare modernization act on dually eligible persons with psychiatric diagnoses: a New York State case study.
    Jones K; Siegel C; Bertollo DN; Samuels J
    Psychiatr Serv; 2009 Apr; 60(4):512-9. PubMed ID: 19339327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transition to Medicare Part D: an early snapshot of barriers experienced by younger dual eligibles with disabilities.
    Hall JP; Kurth NK; Moore JM
    Am J Manag Care; 2007 Jan; 13(1):14-8. PubMed ID: 17227199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mental health in the Medicare Part D drug benefit: a new regulatory model?
    Donohue J
    Health Aff (Millwood); 2006; 25(3):707-19. PubMed ID: 16684735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic grand rounds: the economics of the new medicare drug benefit: implications for people with mental illnesses.
    Donohue JM
    Psychiatr Serv; 2005 Jun; 56(6):645-7. PubMed ID: 15939937
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.